MedTrace Logo

Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer

NCT04593381 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2024-05-23

No results posted yet for this study

Summary

This is a prospective, multicenter, Phase II study aimed at defining the activity and safety of SBRT in MPR-OC. Clinical and imaging data as well as SBRT parameters would be analyzed with the aim to identify potential predictors of response to treatment and clinical outcome.

Conditions

  • Ovarian Neoplasms
  • Recurrent Ovarian Carcinoma
  • Oligometastatic Disease

Interventions

RADIATION

Stereotactic body radiotherapy

All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.

Sponsors & Collaborators

  • Fondazione Policlinico Universitario A. Gemelli, IRCCS

    collaborator UNKNOWN

  • Gemelli Molise Hospital

    lead OTHER

Principal Investigators

  • Gabriella Macchia · Radiotherapy Unit, Gemelli Molise

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04593381 on ClinicalTrials.gov